Journal article
Nanoallergen platform for detection of platin drug allergies
Journal of allergy and clinical immunology, v 143(5), pp 1957-1960.e12
01 May 2019
PMID: 30682456
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Platinum-based antineoplastic agents (platins) are the most frequently used chemotherapeutics in patients with a variety of cancers, such as ovarian, colorectal, endometrial, and pancreatic cancer among others, and their use is associated with an increase in drug hypersensitivity reactions (DHRs). In particular, 2 commonly used platins, oxaliplatin and carboplatin, have high rates of DHR: carboplatin DHR rates range from 9% to 27%, whereas oxaliplatin DHR rates are as high as 25% and typically manifest between the fifth and seventh infusions. Furthermore, the majority of DHRs to these drugs are IgE mediated, which typically results in severe and anaphylactic reactions. An approach to prevent these IgE-mediated DHRs is rapid drug desensitization (RDD). RDD induces temporary tolerization by delivering incremental suboptimal doses in a short period of time, allowing patients to receive the full therapeutic dose without or with minimal reactions.
Metrics
Details
- Title
- Nanoallergen platform for detection of platin drug allergies
- Creators
- Peter E. Deak - Drexel University, Chemical and Biological EngineeringBaksun Kim - University of Notre DameAther Adnan - Brigham and Women's HospitalMarina Labella - Brigham and Women's HospitalLeticia De las Vecillas - Marqués de Valdecilla University HospitalMariana Castells - Brigham and Women's HospitalBasar Bilgicer (Corresponding Author) - University of Notre Dame
- Publication Details
- Journal of allergy and clinical immunology, v 143(5), pp 1957-1960.e12
- Publisher
- Elsevier
- Number of pages
- 16
- Grant note
- R01AI108884 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) R01AI108884 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Ovations for the Cure Fund
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Chemical and Biological Engineering
- Web of Science ID
- WOS:000466784600038
- Scopus ID
- 2-s2.0-85061393034
- Other Identifier
- 991019376908504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Allergy
- Immunology